Workflow
Cassava Sciences(SAVA)
icon
Search documents
Cassava Sciences(SAVA) - 2021 Q3 - Quarterly Report
2021-11-15 13:36
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-Q _____________________ (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from ___________ to ___________ Commission File Number: 000-29959 _______________ Cassava Sciences, Inc. (Exact nam ...
Cassava Sciences(SAVA) - 2021 Q2 - Quarterly Report
2021-08-04 21:20
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-Q _____________________ (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from ___________ to ___________ Commission File Number: 000-29959 _______________ Cassava Sciences, Inc. (Exact name of ...
Cassava Sciences(SAVA) - 2021 Q1 - Quarterly Report
2021-04-29 20:52
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-Q _____________________ (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 incorporation or organization) Identification Number) 7801 N. Capital of Texas Highway, Suite 260, Austin, TX 78731 (512) 501-2444 (Address, incl ...
Cassava Sciences(SAVA) - 2020 Q4 - Annual Report
2021-03-23 21:05
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________ Form 10-K _______________ (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 000-29959 Cassava Sciences, Inc. (Exact name of registrant as specified in its charter) (Sta ...
Cassava Sciences (SAVA) Presents At H.C. Wainwright 21st Annual Global Investment Conference - Slideshow
2019-09-16 16:49
Remi Barbier - President & CEO Corporate Overview September 2019 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statement about our prospects for growth, intellectual property protection, market size, competitive position, regulatory agency action, and the anticipated development, timing, data readouts and therapeutic scope and value of our development stage products. You should not place ...
Cassava Sciences (SAVA) Presents At Maxim Group's Alzheimer's Disease Conference - Slideshow
2019-06-27 18:12
NASDAQ: SAVA CORPORATE OVERVIEW June 2019 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statement about our prospects for growth, intellectual property protection, market size or growth, competitive position, regulatory agency action, and the anticipated development, timing, data readouts and therapeutic scope and value of our development stage products. You should not place undue relianc ...